2019 annual financial data

Inhibikase Therapeutics 2019 Net margin

Direct answer

Net margin was -511.95%.

Operating income was -5.7M USD and net income was -5.75M USD.
Operating cash flow was -338,290 USD.

Get free Inhibikase Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
1.12M USD
Operating income
-5.7M USD
Net income
-5.75M USD
Operating cash flow
-338,290 USD